4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

ALPHARETTA, Ga., Nov. 8, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Michael Greiner, interim chief executive officer, will participate in a fireside chat at the UBS 2024 Healthcare Conference on Tues., Nov. 12 at approximately 2:45 p.m. Pacific Time. A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site. About Avanos Medical, Inc. Avanos Medical, Inc. (NYSE:AVNS) is a medical technology company focused on delivering clinically superior medical device so

Advancement to reduce dislodgement in feeding tube retention systems ALPHARETTA, Ga., Nov. 5, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced the launch of its newly designed CORGRIP SR Nasogastric/Nasointestinal Tube Retention System, further expanding its comprehensive Enteral Feeding portfolio. The new CORGRIP SR system, featuring a monofilament thread, is a nasal bridle solution designed to offer numerous advantages over tape. CORGRIP SR is designed to reduce the risk of dislodgement and the complications associated with replacement of nasal tubes. C

ALPHARETTA, Ga., Oct. 30, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported third quarter 2024 financial results and announced the retirement of its CEO, Joe Woody. Gary Blackford, Avanos Board Chairman, noted, "Joe has decided to retire after leading Avanos for the past seven years. Joe has agreed to assist the Company in the transition of leadership, and will continue to consult with the Company through April of next year. Avanos is better positioned financially and organizationally today to achieve its longer-term value creation goals because of Joe's lea

ALPHARETTA, Ga., Oct. 23, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2024 on Wednesday, Oct. 30 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer. To join the live conference call, dial 1-800-836-8184 in the United States. A

ALPHARETTA, Ga., Sept. 9, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Michael Greiner, senior vice president, chief financial officer, and chief transformation officer will participate in a fireside chat at CL King's virtual 22nd Annual Best Ideas Conference 2024 on Mon., Sept. 16 at approximately 9:30 a.m. Eastern Time. A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site. About Avanos Medical, Inc. Avanos Medical, Inc. (NYSE:AVNS) is a medical technol

New Collaboration Marks GAME READY as the Official Recovery Partner of One of the NFL's Top Defensive Players ALPHARETTA, Ga., Sept. 9, 2024 /PRNewswire/ -- GAME READY, an Avanos Medical, Inc. (NYSE:AVNS) brand and a leader in innovative injury treatment and recovery technology, is proud to announce its new partnership* with NFL defensive end and San Francisco 49ers star, Nick Bosa. As part of this exciting collaboration, GAME READY has been named the Official Recovery Partner of Nick Bosa. Nick Bosa, known for his relentless drive on the field and commitment to peak performan

ALPHARETTA, Ga., July 31, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported second quarter 2024 financial results. "We are pleased with our second quarter results and the cumulative progress we have made at the mid-year point," said Joe Woody, Avanos's chief executive officer. Woody continued, "Digestive Health continues to lead in delivering high-single digit growth while Pain Management and Recovery performance is improving with quarter-over-quarter sequential growth, and we are seeing meaningful progress on our other transformation objectives, all of whic

ALPHARETTA, Ga., July 24, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2024 on Wednesday, July 31 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer. To join the live conference call, dial 1-800-836-8184 in the United States.

ALPHARETTA, Ga., July 1, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Indrani Franchini has been appointed as a new independent member of the Avanos board of directors. "We are excited to welcome Indrani Franchini to the Avanos board," remarked Gary Blackford, Avanos board chair. "Her experience with a broad range of global companies will be invaluable to Avanos as we pursue our vision of getting patients back to the things that matter." "Avanos is committed to addressing some of today's most important healthcare needs and I am thrilled to join it

ALPHARETTA, Ga., May 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Sigfrido (Sig) Delgado has been appointed senior vice president, integrated supply chain. In this role, Delgado will lead the teams focused on implementing continuous improvements within the Company's end-to-end supply chain capabilities worldwide. Delgado joins Avanos from Jabil Healthcare, the industry's largest global provider of healthcare manufacturing solutions, where he most recently served as vice president of its global medical technology business. His background includ

KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight

CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00

Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously

Morgan Stanley reiterated coverage of Avanos Medical with a rating of Underweight and set a new price target of $36.00 from $37.00 previously

Morgan Stanley reiterated coverage of Avanos Medical with a rating of Underweight and set a new price target of $41.00 from $45.00 previously

Stephens downgraded Avanos Medical from Overweight to Equal-Weight and set a new price target of $45.00 from $60.00 previously

Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $47.00 from $55.00 previously

ALPHARETTA, Ga., Oct. 30, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported third quarter 2024 financial results and announced the retirement of its CEO, Joe Woody. Gary Blackford, Avanos Board Chairman, noted, "Joe has decided to retire after leading Avanos for the past seven years. Joe has agreed to assist the Company in the transition of leadership, and will continue to consult with the Company through April of next year. Avanos is better positioned financially and organizationally today to achieve its longer-term value creation goals because of Joe's lea

ALPHARETTA, Ga., Oct. 23, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2024 on Wednesday, Oct. 30 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer. To join the live conference call, dial 1-800-836-8184 in the United States. A

ALPHARETTA, Ga., July 31, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported second quarter 2024 financial results. "We are pleased with our second quarter results and the cumulative progress we have made at the mid-year point," said Joe Woody, Avanos's chief executive officer. Woody continued, "Digestive Health continues to lead in delivering high-single digit growth while Pain Management and Recovery performance is improving with quarter-over-quarter sequential growth, and we are seeing meaningful progress on our other transformation objectives, all of whic

ALPHARETTA, Ga., July 24, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2024 on Wednesday, July 31 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer. To join the live conference call, dial 1-800-836-8184 in the United States.

ALPHARETTA, Ga., May 2, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2024 financial results. "As we begin the second year of our three-year transformation initiative, we are pleased with our first quarter results," said Joe Woody, Avanos's chief executive officer. Woody added, "We continue to make progress on our long-term margin expansion targets, are delivering on our Digestive Health growth objectives and have made improvements in our Pain Management and Recovery franchise that will support our mid-single digit growth in the back half o

ALPHARETTA, Ga., April 25, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2024 on Thursday, May 2 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer. To join the live conference call, dial 1-800-836-8184 in the United States. A s

ALPHARETTA, Ga., Feb. 20, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported fourth quarter and full-year 2023 results. "We were very pleased with the overall execution on our transformation initiative last year, which sets the foundation for more profitable growth in 2024 and for reaching our mid-term financial targets in 2025," said Joe Woody, Avanos's chief executive officer. Woody continued, "We believe we are poised to maintain the positive momentum in our Digestive Health portfolio and we are also confident that our strategy for the Pain Management and

ALPHARETTA, Ga., Feb. 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2023 on Tuesday, Feb. 20 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president and chief financial officer. To join the live conference call, dial 877-240-5772 in the United States. A simultaneous webcas

ALPHARETTA, Ga., Jan. 4, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported selected, unaudited preliminary financial results for the fourth quarter and full-year ended December 31, 2023 and revised its preliminary revenue outlook for 2024. Preliminary Unaudited Financial Results For the fourth quarter ended December 31, 2023, Avanos Medical, Inc. (the "Company") expects net sales in the range of $170 million to $173 million, a decrease of approximately 6.5% to 4.5% compared to the same period in 2022, with net sales for the year ended December 31, 2023 anti

ALPHARETTA, Ga., Aug. 9, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported second quarter 2023 financial results. "We posted solid second quarter earnings, with Digestive Health continuing to deliver above-market growth and expanded margins," stated Joe Woody, Avanos's chief executive officer. Woody continued, "Separately, we continue to deliver on our transformation priorities and remain highly focused on implementing our new pain franchise strategy outlined at our Investor Day." Second Quarter 2023 Financial Highlights Total net sales from continuing opera

JMP Securities analyst Daniel Stauder reiterates Avanos Medical (NYSE:AVNS) with a Market Perform.

Avanos Medical (NYSE:AVNS) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.21 by 9.52 percent. This is a 29.63 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $166.100 million which beat the analyst consensus estimate of $162.900 million by 1.96 percent. This is a 4.27 percent increase over sales of $159.300 million the same period last year.

The Nurse Assist voluntary recall was initiated due to concerns about the potential lack of sterility assurance in these water-based products. This deficiency may lead to non-sterile products, posing a risk of the water coming into contact with a patient's surgical site. Any open wound exposed to non-sterile products could potentially put the patient at risk of infection. The pre-filled syringe is the only item in the Avanos feeding tube kit affected by the Nurse Assist recall. As of Feb. 6, 2024, the FDA reported receiving adverse events associated with use of Nurse Assist products and is further evaluating this information. Avanos has not been directly contacted with any reported adverse

Avanos Medical (NYSE:AVNS) reported quarterly earnings of $0.36 per share which missed the analyst consensus estimate of $0.37 by 2.7 percent. This is a 20 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $173.30 million which beat the analyst consensus estimate of $170.43 million by 1.68 percent. This is a 4.57 percent decrease over sales of $181.60 million the same period last year.

2024 Outlook The Company expects 2024 net sales to be between $685 and $705 million, which assumes organic growth between 3% to 6%, excluding the impact of the product portfolio rationalization under the Transformation Process. Adjusted gross profit margins are expected to be between 59.5% and 60.5%, adjusted SG&A as a percentage of revenue is expected to be between 41% and 42%, and adjusted diluted earnings per share are expected to be between $1.30 to $1.45.

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. • Fresenius Medical Care (NYSE:FMS) is projected to report quarterly earnings at $0.32 per share on revenue of $5.35 billion. • NexPoint Residential (NYSE:NXRT) is projected to report earnings for its fourth quarter. • Summit Therapeutics (NASDAQ:SMMT) is likely to report earnings for its fourth quarter. • Axsome Therapeutics (NASDAQ:AXSM) is projected to report quarterly loss at $1.15 per share on revenue of $67.69 million. • Gran Tierra Energy (AMEX:GTE) is expected to report quarterly loss at $0.13 per share on revenue of $60 thousand. • O

Shares of Mobileye Global Inc. (NASDAQ:MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance. For the fourth quarter, the company expects revenue of $634 million-$638 million (vs. $636.39 million) and adjusted operating income of $241 million-$247 million. The company's previous implied guidance was $623 million-$648 million in revenue. Wolfe Research analyst Shreyas Patil downgraded Mobileye Global from Outperform to Peer Perform. Mobileye Global shares dipped 23.5% to $30.37 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Minim, Inc. (NASDAQ:MINM) shares jumped 170.2% t